Chemotherapy and immunotherapy of bovine leukosis.
To prevent the progression of the disease, we treated leukemic or preleukemic cows with (1) adriamycin (ADM) entrapped in liposomes conjugated with monoclonal antibody, c143, against tumor-associated antigens (TAA) of bovine leukemic cells and (2) an immunotherapy using an immunopotentiator consisting of the cell wall skeleton of Nocardia rubra (N-CWS). Five leukemic or preleukemic cows with TAA-positive peripheral blood lymphocytes (PBL) received four injections of ADM alone (0.4 mg/kg body weight) or c143-conjugated liposomes containing the same dose of ADM (L-ADM-c143) through the jugular vein at about 4-day intervals. In three animals treated with L-ADM-c143, the TAA-positive cells gradually decreased with treatment and finally two animals became TAA-negative during a 6-week period and a 14-week period after treatment, respectively. About 6 weeks later, however, TAA-positive cells gradually increased. In the control, two animals treated with ADM alone showed no decrease of TAA-positive cells. Five TAA-positive animals with enlarged subcutaneous lymphatic nodules, each nodule estimated to be from 1 to 4 cm3 in size, were treated by injection of N-CWS into the tumors. Complete regression of tumor was observed in seven out of ten tumors treated in five animals. Decrease of TAA-positive cells was also observed in PBL for all five treated animals. In one animal, the TAA-positive cells remained low for at least 280 days after treatment. This study documents that ADM treatment and intralesionally administered N-CWS are effective in the treatment of bovine leukosis.
Onuma
M
M
Department of Veterinary Microbiology, Rakuno Gakuen University, Ebetsu, Japan.
Yasutomi
Y
Y
Yamamoto
M
M
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000957:Antigens, Viral, Tumor; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy* / Q000276:immunology / Q000628:therapy; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004337:Drug Carriers; D007167:Immunotherapy; D007938:Leukemia / Q000188:drug therapy / Q000628:therapy / Q000662:veterinary*; D001909:Leukemia Virus, Bovine; D008081:Liposomes; D011289:Preleukemia / Q000188:drug therapy / Q000628:therapy / Q000662:veterinary
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D000957:Antigens, Viral, Tumor; D004337:Drug Carriers; D008081:Liposomes; D004317:Doxorubicin